A new HPLC-based assay for the measurement of fructosamine-3-kinase (FN3K) and FN3K-related protein activity in human erythrocytes
-
Anne Hellwig
Abstract
Background: An impact on glycation, and possibly on diabetic complications, is attributed to fructosamine-3-kinase (FN3K) and its related protein (FN3K-RP) because they degrade Amadori compounds in vivo. Little is known about individual differences in FN3K-RP activity, which might contribute to an individual risk for diabetic complications.
Methods: An HPLC-based activity assay for FN3K-RP in erythrocytes with the substrate N-α-hippuryl-N-ε-psicosyllysine was developed. The activities of FN3K and FN3K-RP were also analysed in erythrocytes of 103 consecutive participants of a health-care survey amongst a high-risk group for diabetes. The potential associations of these activities with the subjects’ health background (anthropometric data, glucose tolerance and HbA1c, blood lipids, history of metabolic diseases in the subjects and their families, and medication) were examined.
Results: The interindividual variability of FN3K-RP is less pronounced than that of FN3K [60–135 vs. 2.8–12.5 mU/g haemoglobin (Hb)]. No correlations with age, sex, body weight, blood cholesterol, or plasma glucose in an oral glucose tolerance test were observed. Subjects with kidney disease had higher activity of mainly FN3K-RP [111±15 vs. 98±18 mU/g Hb, mean±standard deviations (SDs), n=16 vs. 87, p=0.009], whereas subjects whose parents or siblings had a stroke showed lower FN3K activity (6.2±1.6 vs. 7.1±1.8 mU/g Hb, mean±SD, n=24 vs. 66, p=0.040).
Conclusions: There is a likely impact of FN3K and FN3K-RP on the glycation cascade in vivo with potential positive and negative effects. The new screening method enables further studies to elucidate the function and importance of FN3K-RP.
Conflict of interest statement
Authors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
References
1. Fujita T, Suzuki K, Tada T, Yoshihara Y, Hamaoka R, Uchida K, et al. Human erythrocyte bisphosphoglycerate mutase: inactivation by glycation in vivo and in vitro. J Biochem 1998;124:1237–44.10.1093/oxfordjournals.jbchem.a022243Search in Google Scholar
2. Van Schaftingen E, Collard F, Wiame E, Veiga-da-Cunha M. Enzymatic repair of Amadori products. Amino Acids 2012;42:1143–50.10.1007/s00726-010-0780-3Search in Google Scholar
3. Beisswenger PJ, Howell SK, Nelson RG, Mauer M, Szwergold BS. α-Oxoaldehyde metabolism and diabetic complications. Biochem Soc Trans 2003;31:1358–63.10.1042/bst0311358Search in Google Scholar
4. Barski OA, Tipparaju SM, Bhatnagar A. The aldo-keto reductase superfamily and its role in drug metabolism and detoxification. Drug Metab Rev 2008;40:553–624.10.1080/03602530802431439Search in Google Scholar
5. Collard F, Vertommen D, Fortpied J, Duester G, Van Schaftingen E. Identification of 3-deoxyglucosone dehydrogenase as aldehyde dehydrogenase 1A1 (retinaldehyde dehydrogenase 1). Biochimie 2007;89:369–73.10.1016/j.biochi.2006.11.005Search in Google Scholar
6. Delpierre G, Veiga-da-Cunha M, Vertommen D, Buysschaert M, van Schaftingen E. Variability in erythrocyte fructosamine 3-kinase activity in humans correlates with polymorphisms in the FN3K gene and impacts on haemoglobin glycation at specific sites. Diabetes Metab 2006;32:31–9.10.1016/S1262-3636(07)70244-6Search in Google Scholar
7. Veiga-da-Cunha M, Jacquemin P, Delpierre G, Godfraind C, Theate I, Vertommen D, et al. Increased protein glycation in fructosamine-3-kinase deficient mice. Biochem J 2006;399: 257–64.10.1042/BJ20060684Search in Google Scholar PubMed PubMed Central
8. Mosca L, Penco S, Patrosso MC, Marocchi A, Lapolla A, Sartore G, et al. Genetic variability of the fructosamine 3-kinase gene in diabetic patients. Clin Chem Lab Med 2011;49:803–8.10.1515/CCLM.2011.133Search in Google Scholar PubMed
9. Mohás M, Kisfali P, Baricza E, Mérei A, Maasz A, Cseh J, et al. A polymorphism within the fructosamine-3-kinase gene is associated with HbA1c levels and the onset of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2009;118:209–12.10.1055/s-0029-1238319Search in Google Scholar PubMed
10. Pácal L, Tanhäuserová V, Svojanovský J, Krusová D, Štěpánková S, Olšovský J, et al. Does genetic variability in the fructosamine-3-kinase play a role in the progression of diabetic nephropathy, morbidity and mortality of diabetics? Diabetologia 2010;53:S135.Search in Google Scholar
11. Soranzo N, Sanna S, Wheeler E, Gieger C, Radke D, Dupuis J, et al. Common variants at 10 genomic loci influence hemoglobin A1c levels via glycemic and nonglycemic pathways. Diabetes 2010;59:3229–39.10.2337/db10-0502Search in Google Scholar PubMed PubMed Central
12. Collard F, Delpierre G, Stroobant V, Matthijs G, van Schaftingen E. A mammalian protein homologous to fructosamine-3-kinase is a ketosamine-3-kinase acting on psicosamines and ribulosamines but not on fructosamines. Diabetes 2003;52:2888–95.10.2337/diabetes.52.12.2888Search in Google Scholar PubMed
13. Fortpied J, Gemayel R, Vertommen D, Van Schaftingen E. Identification of protein-ribulosamine-5-phosphatase as human low-molecular-mass protein tyrosine phosphatase-A. Biochem J 2007;406:139–45.10.1042/BJ20061485Search in Google Scholar PubMed PubMed Central
14. Takahashi S, Izawa Y, Suzuki N. Astroglial pentose phosphate pathway rates in response to high-glucose environments. ASN Neuro 2012;4:71–88.10.1042/AN20120002Search in Google Scholar PubMed PubMed Central
15. Cappai G, Songini M, Doria A, Cavallerano JD, Lorenzi M. Increased prevalence of proliferative retinopathy in patients with type 1 diabetes who are deficient in glucose-6-phosphate dehydrogenase. Diabetologia 2011;54:1539–42.10.1007/s00125-011-2099-3Search in Google Scholar PubMed
16. Kunjara S, Greenbaum AL, Sochor M, Ali M, Flyvbjerg A, Grønbaek H, et al. Effects of long-acting somatostatin analogues on adrenal growth and phosphoribosyl pyrophosphate formation in experimental diabetes. Int J Exp Pathol 2012;93:56–69.10.1111/j.1365-2613.2011.00801.xSearch in Google Scholar PubMed PubMed Central
17. Szwergold BS, Manevich Y, Payne L, Loomes K. Fructosamine-3-kinase-related-protein phosphorylates glucitolamines on the C-4 hydroxyl: novel substrate specificity of an enigmatic enzyme. Biochem Biophys Res Commun 2007;361:870–5.10.1016/j.bbrc.2007.07.127Search in Google Scholar PubMed
18. Delplanque J, Delpierre G, Opperdoes FR, van Schaftingen E. Tissue distribution and evolution of fructosamine 3-kinase and fructosamine 3-kinase-related protein. J Biol Chem 2004;279:46606–13.10.1074/jbc.M407678200Search in Google Scholar PubMed
19. Krause R, Oehme A, Wolf K, Henle T. A convenient HPLC assay for the determination of fructosamine-3-kinase activity in erythrocytes. Anal Bioanal Chem 2006;386:2019.10.1007/s00216-006-0886-3Search in Google Scholar PubMed
20. Hodge JE, Fisher BE. Amadori rearrangement products. Methods Carbohydr Chem 1963;2:99–107.Search in Google Scholar
21. Collard F, Wiame E, Bergans N, Fortpied J, Vertommen D, Vanstapel F, et al. Fructosamine 3-kinase-related protein and deglycation in human erythrocytes. Biochem J 2004;382: 137–43.10.1042/BJ20040307Search in Google Scholar PubMed PubMed Central
22. Delpierre G, Vanstapel F, Stroobant V, van Schaftingen E. Conversion of a synthetic fructosamine into its 3-phospho derivative in human erythrocytes. Biochem J 2000;352:835–9.10.1042/bj3520835Search in Google Scholar
23. Conner JR, Beisswenger PJ, Szwergold BS. The expression of the genes for fructosamine-3-kinase and fructosamine-3-kinase-related protein appears to be constitutive and unaffected by environmental signals. Biochem Biophys Res Commun 2004;323:932–6.10.1016/j.bbrc.2004.08.181Search in Google Scholar PubMed
24. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005;112:2735–52.10.1161/CIRCULATIONAHA.105.169404Search in Google Scholar PubMed
25. American Diabetes Association (ADA). Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33:S62–9.10.2337/dc10-S062Search in Google Scholar PubMed PubMed Central
26. Tsai C-J, Leitzmann MF, Willett WC, Giovannucci EL. Macronutrients and insulin resistance in cholesterol gallstone disease. Am J Gastroenterol 2008;103:2932–9.10.1111/j.1572-0241.2008.02189.xSearch in Google Scholar PubMed
27. Liu C-J. Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese. J Gastroenterol Hepatol 2012;27:1555–60.10.1111/j.1440-1746.2012.07222.xSearch in Google Scholar PubMed
28. Zarrinpar A, Loomba R. The emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2012;36:909–21.10.1111/apt.12084Search in Google Scholar PubMed PubMed Central
29. Barlovic DP, Soro-Paavonen A, Jandeleit-Dahm KA. RAGE biology, atherosclerosis and diabetes. Clin Sci 2011;121:43–55.10.1042/CS20100501Search in Google Scholar PubMed
30. Picchi A, Capobianco S, Qiu T, Focardi M, Zou X, Cao J-M, et al. Coronary microvascular dysfunction in diabetes mellitus: a review. World J Cardiol 2010;2:377–90.10.4330/wjc.v2.i11.377Search in Google Scholar PubMed PubMed Central
31. Prasad A, Bekker P, Tsimikas S. Advanced glycation end products and diabetic cardiovascular disease. Cardiol Rev 2012;20:177–83.10.1097/CRD.0b013e318244e57cSearch in Google Scholar PubMed
©2014 by Walter de Gruyter Berlin Boston
Articles in the same Issue
- Masthead
- Masthead
- Editorial
- Frontiers in research on the Maillard reaction in aging and chronic disease
- Reviews
- Role of the Maillard reaction in aging and age-related diseases. Studies at the cellular-molecular level
- Advanced glycation end-products and skin autofluorescence in end-stage renal disease: a review
- Glucosepane: a poorly understood advanced glycation end product of growing importance for diabetes and its complications
- Mini Reviews
- Post-translational modification derived products (PTMDPs): toxins in chronic diseases?
- Site-specific AGE modifications in the extracellular matrix: a role for glyoxal in protein damage in diabetes
- Augmentation of blood lipid glycation and lipid oxidation in diabetic patients
- Maillard reaction products: some considerations on their health effects
- The Maillard reaction and food allergies: is there a link?
- Perspectives
- Chelation therapy for the management of diabetic complications: a hypothesis and a proposal for clinical laboratory assessment of metal ion homeostasis in plasma
- Genetics and Molecular Diagnostics
- Genetic variability in enzymes of metabolic pathways conferring protection against non-enzymatic glycation versus diabetes-related morbidity and mortality
- General Clinical Chemistry and Laboratory Medicine
- Quantification of glyoxal, methylglyoxal and 3-deoxyglucosone in blood and plasma by ultra performance liquid chromatography tandem mass spectrometry: evaluation of blood specimen
- A new HPLC-based assay for the measurement of fructosamine-3-kinase (FN3K) and FN3K-related protein activity in human erythrocytes
- Increased circulating advanced glycation endproducts (AGEs) in acute trauma patients
- Circulating soluble RAGE increase after a cerebrovascular event
- Pentosidine determination in CSF: a potential biomarker of Alzheimer’s disease?
- Cardiovascular Diseases
- Skin autofluorescence as proxy of tissue AGE accumulation is dissociated from SCORE cardiovascular risk score, and remains so after 3 years
- Plasma advanced glycation end products (AGEs) and NF-κB activity are independent determinants of diastolic and pulse pressure
- Total plasma Nε-(carboxymethyl)lysine and sRAGE levels are inversely associated with a number of metabolic syndrome risk factors in non-diabetic young-to-middle-aged medication-free subjects
- Translational Research Papers
- Advanced glycation end-products induce endoplasmic reticulum stress in human aortic endothelial cells
- Formation of nitri- and nitrosylhemoglobin in systems modeling the Maillard reaction
- Skin aging by glycation: lessons from the reconstructed skin model
- How to help the skin cope with glycoxidation
Articles in the same Issue
- Masthead
- Masthead
- Editorial
- Frontiers in research on the Maillard reaction in aging and chronic disease
- Reviews
- Role of the Maillard reaction in aging and age-related diseases. Studies at the cellular-molecular level
- Advanced glycation end-products and skin autofluorescence in end-stage renal disease: a review
- Glucosepane: a poorly understood advanced glycation end product of growing importance for diabetes and its complications
- Mini Reviews
- Post-translational modification derived products (PTMDPs): toxins in chronic diseases?
- Site-specific AGE modifications in the extracellular matrix: a role for glyoxal in protein damage in diabetes
- Augmentation of blood lipid glycation and lipid oxidation in diabetic patients
- Maillard reaction products: some considerations on their health effects
- The Maillard reaction and food allergies: is there a link?
- Perspectives
- Chelation therapy for the management of diabetic complications: a hypothesis and a proposal for clinical laboratory assessment of metal ion homeostasis in plasma
- Genetics and Molecular Diagnostics
- Genetic variability in enzymes of metabolic pathways conferring protection against non-enzymatic glycation versus diabetes-related morbidity and mortality
- General Clinical Chemistry and Laboratory Medicine
- Quantification of glyoxal, methylglyoxal and 3-deoxyglucosone in blood and plasma by ultra performance liquid chromatography tandem mass spectrometry: evaluation of blood specimen
- A new HPLC-based assay for the measurement of fructosamine-3-kinase (FN3K) and FN3K-related protein activity in human erythrocytes
- Increased circulating advanced glycation endproducts (AGEs) in acute trauma patients
- Circulating soluble RAGE increase after a cerebrovascular event
- Pentosidine determination in CSF: a potential biomarker of Alzheimer’s disease?
- Cardiovascular Diseases
- Skin autofluorescence as proxy of tissue AGE accumulation is dissociated from SCORE cardiovascular risk score, and remains so after 3 years
- Plasma advanced glycation end products (AGEs) and NF-κB activity are independent determinants of diastolic and pulse pressure
- Total plasma Nε-(carboxymethyl)lysine and sRAGE levels are inversely associated with a number of metabolic syndrome risk factors in non-diabetic young-to-middle-aged medication-free subjects
- Translational Research Papers
- Advanced glycation end-products induce endoplasmic reticulum stress in human aortic endothelial cells
- Formation of nitri- and nitrosylhemoglobin in systems modeling the Maillard reaction
- Skin aging by glycation: lessons from the reconstructed skin model
- How to help the skin cope with glycoxidation
